Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Search Results

94 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma.
Pal SK, Tran B, Haanen JBAG, Hurwitz ME, Sacher A, Tannir NM, Budde LE, Harrison SJ, Klobuch S, Patel SS, Meza L, Dequeant ML, Ma A, He QA, Williams LM, Keegan A, Gurary EB, Dar H, Karnik S, Guo C, Heath H, Yuen RR, Morrow PK, Agarwal N, Srour SA. Pal SK, et al. Among authors: srour sa. Cancer Discov. 2024 Jul 1;14(7):1176-1189. doi: 10.1158/2159-8290.CD-24-0102. Cancer Discov. 2024. PMID: 38583184 Free PMC article. Clinical Trial.
Sleeping beauty generated CD19 CAR T-Cell therapy for advanced B-Cell hematological malignancies.
Singh H, Srour SA, Milton DR, McCarty J, Dai C, Gaballa MR, Ammari M, Olivares S, Huls H, De Groot E, Marin D, Petropoulos D, Olson AL, Anderlini P, Im JS, Khouri I, Hosing CM, Rezvani K, Champlin RE, Shpall EJ, Cooper LJN, Kebriaei P. Singh H, et al. Among authors: srour sa. Front Immunol. 2022 Nov 10;13:1032397. doi: 10.3389/fimmu.2022.1032397. eCollection 2022. Front Immunol. 2022. PMID: 36439104 Free PMC article. Clinical Trial.
Impact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantation.
Pasvolsky O, Pasyar S, Bassett RL, Khan HN, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Pasvolsky O, et al. Cancer. 2024 May 1;130(9):1663-1672. doi: 10.1002/cncr.35171. Epub 2023 Dec 21. Cancer. 2024. PMID: 38127583
Chimeric antigen receptor T-cell therapy toxicities.
Greenbaum U, Kebriaei P, Srour SA, Olson A, Bashir Q, Neelapu SS, Rezvani K, Shpall EJ. Greenbaum U, et al. Among authors: srour sa. Br J Clin Pharmacol. 2021 Jun;87(6):2414-2424. doi: 10.1111/bcp.14403. Epub 2020 Aug 7. Br J Clin Pharmacol. 2021. PMID: 32463929 Free article. Review.
The Unique Symptom Burden of Patients Receiving CAR T-Cell Therapy.
Whisenant MS, Srour SA, Williams LA, Subbiah I, Griffin D, Ponce D, Kebriaei P, Neelapu SS, Shpall E, Ahmed S, Wang XS. Whisenant MS, et al. Among authors: srour sa. Semin Oncol Nurs. 2021 Dec;37(6):151216. doi: 10.1016/j.soncn.2021.151216. Epub 2021 Oct 7. Semin Oncol Nurs. 2021. PMID: 34629213
Safety and long-term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single-center phase 1,2 trial.
Khouri IF, Alzahrani K, Kantarjian H, Milton DR, Gulbis AM, Sasaki K, Jain N, Short NJ, Kadia T, Daher M, Rafei H, Im JS, Marin D, Olson AL, Popat U, Qazilbash M, Ramdial J, Rondon G, Srour S, Kebriaei P, Shpall E, Champlin R, Jabbour EJ. Khouri IF, et al. Am J Hematol. 2024 May;99(5):836-843. doi: 10.1002/ajh.27254. Epub 2024 Feb 23. Am J Hematol. 2024. PMID: 38400519 Clinical Trial.
94 results